Fulcrum Therapeutics, Inc.

As of July 29, 2025, Fulcrum Therapeutics, Inc. is considered overvalued with a high P/E ratio of 252 and negative EV to EBIT and EV to EBITDA ratios, indicating a significant decline in investment appeal despite a recent 60.43% year-to-date return.

As of August 11, 2020, Fulcrum Therapeutics, Inc. is considered overvalued with a "risky" rating, reflected by a high P/E ratio of 252, poor return metrics, and a current stock price of $7.17, despite a strong year-to-date performance.

As of June 9, 2025, the trend is mildly bullish with supportive indicators like a bullish MACD and Bollinger Bands, but caution is advised due to bearish signals from the KST and Dow Theory.

As of March 2022, the management team of Fulcrum Therapeutics, Inc. includes Mr. Mark Levin (Independent Chairman), Dr. Robert Gould (President and CEO), and several Independent Directors: Dr. James Collins, Ms. Katina Dorton, Dr. Alan Ezekowitz, Mr. James Geraghty, and Ms. Kate Haviland.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on treating genetically defined rare diseases. As of March 2025, it has a market cap of $347.09 million and reported a net profit of -$18 million.

As of Jun 18, Fulcrum Therapeutics, Inc. has a market capitalization of 347.09 million, with net sales of 80.00 million and a net profit of -0.52 million over the latest four quarters. The company reported shareholder's funds of 243.03 million and total assets of 260.72 million as of Dec 24.